Laplace Benjamin, Calvet Benjamin, Lacroix Aurelie, Mouchabac Stephane, Picard Nicolas, Girard Murielle, Charles Eric
Esquirol Hospital Center, Department of Research and Innovation, 87000 Limoges, France.
Inserm UMR1094, Tropical Neuroepidemiology, Institute of Neuroepidemiology and Tropical Neurology, Université de Limoges, 87025 Limoges, France.
J Pers Med. 2021 May 21;11(6):446. doi: 10.3390/jpm11060446.
Psychiatric disorder management is based on the prescription of psychotropic drugs. Response to them remains often insufficient and varies from one patient to another. Pharmacogenetics explain part of this variability. Pharmacogenetic testing is likely to optimize the choice of treatment and thus improve patients' care, even if concerns and limitations persist. This practice of personalized medicine is not very widespread in France. We conducted a national survey to evaluate the acceptability of this tool by psychiatrists and psychiatry residents in France, and to identify factors associated with acceptability and previous use. The analysis included 397 observations. The mean acceptability score was 10.70, on a scale from 4 to 16. Overall acceptability score was considered as low for 3.0% of responders, intermediate for 80.1% and high for 16.9%. After regression, the remaining factors influencing acceptability independently of the others were prescription and training history and theoretical approach. The attitude of our population seems to be rather favorable, however, obvious deficiencies have emerged regarding perceived skills and received training. Concerns about the cost and delays of tests results also emerged. According to our survey, one of the keys to overcoming the barriers encountered in the integration of pharmacogenetics seems to be the improvement of training and the provision of information to practitioners.
精神疾病的管理基于精神药物的处方。对这些药物的反应往往仍然不足，而且因患者而异。药物遗传学解释了这种变异性的部分原因。药物遗传学检测可能会优化治疗选择，从而改善患者护理，即便相关担忧和局限性依然存在。这种个性化医疗实践在法国并不十分普遍。我们开展了一项全国性调查，以评估法国精神科医生和精神科住院医师对该工具的接受程度，并确定与接受程度和既往使用情况相关的因素。分析纳入了397份观察结果。在4至16分的评分量表上，平均接受度得分为10.70分。总体而言，3.0%的受访者认为接受度得分低，80.1%的受访者认为得分中等，16.9%的受访者认为得分高。回归分析后，独立于其他因素之外影响接受度的剩余因素是处方及培训经历和理论方法。我们调查对象的态度似乎较为积极，然而，在感知技能和接受的培训方面出现了明显不足。对检测结果的成本和延迟也存在担忧。根据我们的调查，克服药物遗传学整合中遇到的障碍的关键之一似乎是改善培训并向从业者提供信息。
